• OPEN AN ACCOUNT
Indian Indices
Nifty
26,068.15 -124.00
(-0.47%)
Sensex
85,231.92 -400.76
( -0.47%)
Bank Nifty
58,867.70 -480.00
( -0.81%)
Nifty IT
36,885.35 -157.95
( -0.43%)
Global Indices
Nasdaq
45,781.42 -378.36
(-0.82%)
Dow Jones
6,560.44 -102.72
(-1.54%)
Hang Seng
48,653.14 -1,170.80
(-2.35%)
Nikkei 225
9,572.31 64.90
(0.68%)
Forex
USD-INR
88.50 -0.07
(-0.08%)
EUR-INR
102.33 -0.31
(-0.31%)
GBP-INR
115.99 -0.49
(-0.42%)
JPY-INR
0.57 0.00
(-0.62%)

EQUITY - MARKET SCREENER

BSE Bharat 22 Index
Industry :  Stock Exchanges
BSE Code
ISIN Demat
Book Value()
1016
N.A
0
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
13.7
5039276.02
EPS(TTM)
Face Value()
Div & Yield %
0
100
2.72
 

Astrazeneca Pharma and Sun Pharma form second brand partnership
Nov 17,2025
Astrazeneca Pharma India and Sun Pharmaceutical Industries announced a second brand partnership for Sodium Zirconium Cyclosilicate (SZC) in India. This exclusive agreement is aimed at further accelerating availability of SZC, an innovative and highly effective treatment for Hyperkalaemia to more patients across India. Under the agreement, both companies will promote, market & distribute SZC in India under different brand names; AstraZeneca will market SZC as Lokelma® whereas Sun Pharma will promote and distribute the therapy as Gimliand®. AstraZeneca will retain the intellectual property rights to SZC and hold the Marketing Authorisation along with the import license of the molecule.